Skip to main content

Ruxolitinib + CHOP

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

  • RegistryNCT07278856
  • PhasePhase 1
  • StatusRecruiting
  • ConditionUntreated Nodal T Follicular Helper Cell Lymphoma
  • SponsorCity of Hope Medical Center
How Ruxolitinib + CHOP worksNCT072788561 min

What the film says

Read the transcript

This trial is for adults with nodal T follicular helper cell lymphoma, a type of T cell lymphoma, who have not been treated yet.

The idea: add ruxolitinib, a pill that blocks a protein called Janus kinase, to standard CHOP chemotherapy. Blocking it may help keep cancer cells from growing.

The study looks at safety, the best dose of ruxolitinib, and how well the combination works.

This phase 1 study plans 20 patients. At City of Hope in Duarte, California, Christina Poh leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07278856

    Adults; untreated nodal TFH cell lymphoma; Ruxolitinib blocks Janus kinase; added to CHOP; Safety, best dose, how well it works; Phase 1; 20; City of Hope; Christina Poh

The drug

What is being tested.

Undergo bone marrow biopsy and aspiration

PRIMARY OBJECTIVE: I. Determine the safety of ruxolitinib phosphate (ruxolitinib) in combination with CHOP chemotherapy in untreated nodal TFH cell lymphoma patients. SECONDARY OBJECTIVES: I. Determine the tolerability and preliminary clinical efficacy of Ia. Ruxolitinib in combination with CHOP chemotherapy in untreated nodal TFH cell lymphoma; Ib.

Ruxolitinib monotherapy maintenance for nodal TFH cell lymphoma patients who achieve a response (partial response [PR] or complete response [CR]) with ruxolitinib + CHOP chemotherapy. EXPLORATORY OBJECTIVES: I. Describe preliminary survival outcomes. II. Describe the relative dose intensity of CHOP chemotherapy backbone.

The study

How the trial runs.

This phase I trial tests the safety, side effects and best dose of ruxolitinib in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy and how well the combination works in treating patients with untreated nodal T-follicular helper (TFH) cell lymphoma. Ruxolitinib phosphate blocks a protein called janus kinase, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body's immune response.

Ruxolitinib phosphate is a type of tyrosine kinase inhibitor. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Doxorubicin is a type of anthracycline antitumor antibiotic.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Ability to understand and willingness to sign a written informed consent document
  • Documented informed consent of the participant and/or legally authorized representative.
  • Assent, when appropriate, will be obtained per institutional guidelines
  • Be ≥ 18 years of age on day of signing informed consent
  • Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale (PS) at time of enrollment. Patients with a performance status of 2 on the ECOG scale due to lymphoma may be eligible with principal investigator (PI) approval

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.